poisar

Stocks · News reference

Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at SITC 2026 Annual Meeting

Fiscal.ai

Elicio Therapeutics announced it will present new data from its Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncDelveinsight

    Cancer Vaccines Clinical Trial Pipeline Boom as 200+ Companies are in the Race for Better Treatments | DelveInsight

    Over 200 companies are advancing cancer vaccine development with 200+ pipeline candidates in clinical trials. Recent positive Phase III results for intismeran autogene (mRNA-4157) in melanoma and encouraging data for TG4050 in head and neck cancer are driving momentum. However, challenges including clinical efficacy uncertainties, manufacturing complexity, high production costs, and patient selection barriers remain obstacles to broader commercialization.